TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05660850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6599
Description: GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-6599
Description: GDC-6599 will be administered Days 1- 14 and on Days 29-42 as film-coated tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDC-6599-matching placebo
Description: GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDC-6599-matching placebo
Description: GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDC-6599-matching placebo
Description: GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDC-6599-matching placebo
Description: GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GDC-6599-matching placebo
Description: GDC-6599-matching placebo will be administered Days 1- 14 and on Days 29- 42. as film-coated tablets

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol challenge tests will be performed during screening and at least 2.5 hours following study drug administration at Study Visits 2, 4, 5 and 7
Study: NCT05917769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocabdo exercises
Description: The exercises created by Dr. Rocabado, will be performed by the patient at home, consist of six different exercises and six repetitions of each exercise, performed six times per day.~It consists of Tongue 'Clucking', Controlled TMJ Rotation on Opening, Mandibular Rhythmic Stabilization, Upper Cervical Distraction, Axial Extension of the Cervical Spine and Shoulder Girdle Retraction. This group will only perform Rocabdo exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural correction exercises
Description: * Posture correction exercises will be performed six times a day for six days.~* Patient will be assessed on the first day and then on the last day of the treatment, i.e., on 6th day the patient will be re-assessed after they have performed posture correction exercises.~* Posture correction exercises consist of chin tuck in, chest stretch, wall stretch, on your Back chest stretch and face down arm lifts.
Study: NCT05623202

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level behavior-change intervention to strengthen food- and diet-related capital to promote food security and diet quality among low-income Hispanic/Latino adults
Description: The behavior-change intervention with low-income Hispanic/Latino adults will mobilize existing sources of human, material, social, and cultural capital at the individual, household, social, and community level, and will include a nutrition education component and a food access component.
Study: NCT05077631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACD856
Description: Single oral doses of ACD856 administered in a fasted state in escalation schedule of dose 1, dose 2, dose 3, dose 4, dose 5, dose 6 and dose 7. The escalation schedule may be adapted based on evaluation by internal Safety Review Committee.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACD856 (fed cohort)
Description: Single oral dose of ACD856 in fed state of either dose 4 or dose 5.
Study: NCT04879355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal needle (25G)
Description: Fine needle aspiration from thyroid nodules using a 25G spinal needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fine needle (25G)
Description: Fine needle aspiration from thyroid nodules using a conventional 25G fine needle
Study: NCT05516134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE at Home
Description: The All About Me (AAM) app will consist of Serious Digital Health Games for PWD. The market-ready version of the app will consist of five components. (1) The Fun Facts About Me Game will be used when a PWD is moving into LTC. The goal of the game is to provide an enjoyable way for family members and PWD to provide important information about the PWD's background. (2) The Resident Game Bundle will consist of SDHGs that will allow PWD to learn about one another in an enjoyable way. (3) The My Residents Module will provide staff with a convenient way to view information about a PWD with whom they will be working. Staff will launch this module from any device. (4) The Meet the Staff Module, which will be developed and tested in a future Phase II study, will allow residents to learn about staff members at their community. (5) The AAM Training Modules will provide staff and family members with access to video-based training modules that describe how to use relevant portions of the app
Study: NCT05665751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-3595 Dose 1
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-3595 Dose 2
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study: NCT05168969

Intervention type: OTHER
Intervention: Questionnaire
Description: The families and health care providers will be invited to fill in a questionnaire related to hyperekplexia (clinical, pharmacological, and genetic data).
Study: NCT06008067

Intervention type: RADIATION
Intervention: tricuspid annular plane systolic excursion (TAPSE)
Description: Echocardiography

Intervention type: RADIATION
Intervention: tricuspid annular plane systolic excursion (TAPSE)
Description: Echocardiography
Study: NCT04548609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Study: NCT06351748

Intervention type: DRUG
Intervention: Semaglutide
Description: Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.
Study: NCT03706131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical mobilisation
Description: manual therapy
Study: NCT05331625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Offering Additional Resources to Promote Symptom Management
Description: Participants will be offered additional resources to promote symptom management.
Study: NCT05695417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTX-TKI
Description: Injection of OTX-TKI

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham Injection of OTX-TKI
Study: NCT06045104

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling
Description: Wheat Soy Blend Plus Plus (WSB++) with nutrition counselling

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
Description: 15 Micro Nutrient Powder (15 MNP) with improved nutrition counselling
Study: NCT05395767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Anterior Cruciate Ligament reconstruction using living donor hamstring allograft from a parent donor
Description: The Parent donor will undergo hamstring tendon graft harvest under general anaesthesia in a routine fashion in one theatre. The Graft material will be transported thorough to the adjacent theatre, where the child will be anaesthetised and undergoing arthroscopy of their injured knee in preparation for receiving the graft. ACL reconstruction Surgery will be undertaken in the child recipient as per the Surgeons usual technique, +/- meniscus repair +/- lateral tenodesis as required.
Study: NCT05353309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Angioplasty
Description: Angioplasty Iliac done following standard practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Angioplasty with D images
Description: Angioplasty Iliac under additional 3D Images merged as surgery support
Study: NCT06143774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-920 Oral Gel (10 mg and 30 mg)
Description: TRX-920 Oral Gel will be administered orally at a week (BIW) in an 8-week cycle. No food should be taken 2 hours before and 1 hour after taking TRX-920. The dose escalation/de-escalation rules will be based on definitions of dose-limiting toxicity (DLT) and will be monitored during the first treatment cycle (i.e., the first 4 weeks post the first dose).~The starting dose will be 1 mg and the dosing frequency is twice every week (BIW). Subjects will be assigned to a dose level in sequential cohorts based on the order of their enrollment. The dose escalation will follow a 3+3 design and doses escalate from approximately 1 mg BIW, 2 mg BIW, 4 mg BIW, 8 mg BIW, and 16mg BIW and the doses for subsequent cohorts will be determined by Safety Review Committee (SRC). Dose escalation will be stopped till the maximum tolerated dose (MTD) is reached or identified.
Study: NCT06639308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Flexor Hallucis longus tendon transfer to tendon achilles
Description: The endoscopic FHL tendon transfer is usually performed with the scope introduced through the posterolateral portal and instruments through the posteromedial portal. The FHL tendon must be identified during hindfoot working area creation. First, the calcaneoplasty is completed as described. Next, the FHL tendon is harvested. A tunnel was created into calcenous the tendon is introduced into the tunnel and the tendon is secured with an interference screw of same size than the tunnel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flexor Hallucis longus transfer to tendon achilles
Description: The FHL tendon can be approached through the posterior longitudinal incision The FHL is confirmed by digital retraction of the tendon, watching for flexion of the hallux. Dissection of the FHL tendon is followed to the posterior talus and FHL tunnel, remaining lateral to avoid the neurovascular bundle. Release of the fibro-osseous tunnel along the posterior talus is necessary to gain length. With the hallux and ankle plantar flexed, the FHL tendon is transected as distally as possible. The tendon is fixed to the calcaneus just anterior to the Achilles stump insertion by an interference screw.
Study: NCT06463574

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-adhesive resin restoration
Description: Light cured, hybrid resin composite material which contains polymerization modulator that lessens its degree of polymerization shrinkage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-adhesive resin restoration
Description: Light cured, hybrid resin composite material which contains polymerization modulator that lessens its degree of polymerization shrinkage
Study: NCT04592744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II infusion for Intraoperative management during liver transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
Study: NCT06299709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC granules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC granules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC granules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC granules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC granules for oral administration.
Study: NCT06251895

Intervention type: OTHER
Intervention: DKA protocol
Description: IV fluids and IV insulin as per guidelines. reference 1-2

Intervention type: OTHER
Intervention: DKA protocol
Description: IV fluids and IV insulin as per guidelines. reference 1-2

Intervention type: OTHER
Intervention: DKA protocol
Description: IV fluids and IV insulin as per guidelines. reference 1-2
Study: NCT04592744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Vasopressor infusion for management of Intraoperative hypotension in liver transplantation.
Study: NCT05144204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet
Description: Low FODMAP diet instruction to irritable bowel syndrome patients.
Study: NCT06316115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In Patıents Wıth Dıabetıc Foot Ulcer, Effect On Paın And Anxıety Of Stress Ball Use Durıng Sharp Debrıdement
Description: Patients in this group participating in the study will be given a stress ball and asked to use it before the debridement procedure, and each patient will be debrided by the same person throughout the procedure. The patient's pain and anxiety will be evaluated by a nurse independent of the research before and after the debridement procedure.
Study: NCT05357547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone 20mg
Description: Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Lactose-sucrose tablets in opaque capsule
Study: NCT06681467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory monitoring band
Description: The only intervention in this study is the application of two CE marked study approved chest bands- the Go direct respiratory sensor and a biosignal respiration belt
Study: NCT06324448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS self-administered at home once a day for 28 consecutive days for a total of 28 sessions (one session consists of 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea)).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS self-administered at home once a day for 28 consecutive days for a total of 28 sessions (one session consists of 20 minutes through two saline-soaked sponge electrodes (diameter 6cm) using the YMS-201B (Ybrain Inc, South Korea)).
Study: NCT04866771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Noninvasive brain stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS + anodal tDCS
Description: Fake noninvasive brain stimulation or anodal noninvasive brain stimulation
Study: NCT06680609

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nefopam 20 MG/ML
Description: The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing nefopam 20 mg was infused over 20 min

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: The unlabeled interventional drug solution was administered one at the beginning of surgery. A 10 mL solution containing placebo diluted with normal saline was infused over 20 min
Study: NCT06681688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}
Description: Eyes in the Study Arm will be treated with the following intraoperative interventions: Intracameral (OMIDRIA) phenylephrine 1.0%/ketorolac 0.3%, intracameral moxifloxacin (0.5%), and subconjunctival triamcinolone acetonide (0.4 mL, 10mgs/mL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
Description: On the Day of Surgery, eyes in the Control Arm will receive in-office drops administered by study staff according to the following schedule:~* In pre-operative holding: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* Immediately prior to surgery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%)~* At the conclusion of surgery while still in the operating room: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)~* Any time in postoperative recovery: 1 drop ketorolac (0.5%), 1 drop moxifloxacin (0.5%), 1 drop prednisolone acetate (1%)
Study: NCT06310525

Intervention type: OTHER
Intervention: Drowning incident
Description: Drowning was defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid.

Intervention type: OTHER
Intervention: Drowning incident
Description: Drowning was defined by the WHO in 2002 as the process of experiencing respiratory impairment from submersion or immersion in liquid.
Study: NCT06614829

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stratafix Suture
Description: Stratafix sutures are barbed and have an antimicrobial coating. The barbs maintain tension during and allows for knotless suturing. The antimicrobial coating inhibits bacterial colonization of the wound.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DERMABOND PRINEO
Description: DERMABOND™ PRINEO™ Skin Closure System is a sterile, liquid topical skin adhesive. It also incorporates a self-adhering mesh that is applied to the approximated skin edges to provide temporary skin edge alignment until the liquid adhesive is applied to achieve skin closure. It forms a strong, flexible, waterproof microbial barrier-as long as the adhesive film remains intact-that falls off naturally after 7-14 days.~Dermabond Prineo system will be applied to the skin for skin closure.
Study: NCT06680739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 300 mg IV as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 300 mg IV as a single dose
Study: NCT04893096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR202
Description: Each patient will be treated for 24 weeks and received a total of 9 doses. During the first treatment cycle, MOR202 will be administered weekly. For the following 5 months, patients will receive one dose every 4 weeks.
Study: NCT06640062

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Patients received ultrasound-guided erector spinae plane block.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oblique subcostal transversus abdominis plane block
Description: Patients received ultrasound-guided oblique subcostal transversus abdominis plane block.
Study: NCT06641362

Intervention type: DEVICE
Intervention: Ultra High Frequency Electrocardiogram (UHF-ECG)
Description: Electrocardiograms used on participants scheduled to undergo pacemaker implantation for bradycardia and/or heart failure.
Study: NCT06637007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide Tablets combined with AK112
Description: Chidamide Tablets 30mg/day, po.Bid; AK112（10mg/kg or 20mg/kg）, ivgtt, Q3W.
Study: NCT06641284

Intervention type: DRUG
Intervention: Spironolactone
Description: All patients will receive Spironolactone as a part of their GDMT for Heart Failure

Intervention type: DRUG
Intervention: Spironolactone
Description: All patients will receive Spironolactone as a part of their GDMT for Heart Failure
Study: NCT06637839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Locomotor Training Program
Description: The moderate-intensity program prescribes participants to exert 50-59% of their heart rate (HR) reserve, or a score of 13-15 on Borg's rating of perceived exertion (RPE) scale.
Study: NCT04508335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reia Vaginal Pessary
Description: Reia Vaginal Pessary
Study: NCT06708754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) Therapy
Description: PBM is a low-intensity form of light therapy and employs visible or near-infrared (NIR) light generated from a laser or Light Emitting Diode (LED).~In this study, PBM will be delivered using an LED device emitting 660 and 850nm with the purpose of research. The output power typically ranges from 5 to 200 mW with wavelengths ranging 600-1,000nm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham PBM
Description: Sham PBM will be delivered using a matching shame device that emits no output power.
Study: NCT06707246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 MG; Tofacitinib 11mg
Description: Tofacitinib tablet 11mg per tablet; Secukinumab 150mg/ml